300725 药石科技
2026/09 - 九个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入1,634,16415.16%1,974,4781,688,6201,725,2041,594,700
减:营业总成本1,462,38314.11%1,773,8591,441,9601,487,2121,296,321
    其中:营业成本1,096,01811.85%1,366,0231,046,010991,669869,498
               财务费用31,77623.97%31,86228,29854,301(1,875)
               资产减值损失(29,205)-44.78%(30,593)(60,311)(37,720)(9,212)
公允价值变动收益6,499244.54%6789,361(21,326)1,986
投资收益18,652-13.82%36,28135,43711,35312,634
    其中:对联营企业和合营企业的投资收益(621)-56.38%(994)(385)(1,721)(7,149)
营业利润173,84133.32%210,483251,205184,600296,706
利润总额171,11033.44%207,609248,896221,375323,263
减:所得税费用19,89434.02%23,87429,35624,014(2,627)
净利润151,21633.36%183,736219,540197,361325,891
减:非控股权益--------011,667
股东净利润151,21633.36%183,736219,540197,361314,224

市场价值指针
每股收益 (元) *0.64915.19%0.8801.1000.9901.580
每股派息 (元) *0.100--0.2800.2800.3100.100
每股净资产 (元) *19.617-35.84%26.94614.32513.55112.676
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容